Key Points
- Insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics at an average price of $12.00, totaling $19,620 and reducing his holdings by 15.95% to 8,617 shares. He also reported additional sales of 1,635 shares on August 17 and 9,810 shares in June.
- 4D Molecular Therapeutics reported a quarterly loss of $1.04 per share, missing the consensus estimate of a $1.02 loss, while revenue of $3.78 million exceeded expectations of $3.62 million.
- Analyst sentiment remains broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $29.62, although some firms maintain sell ratings. Institutional investors own 99.27% of the company’s shares.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the business's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $12.00, for a total value of $19,620.00. Following the transaction, the insider owned 8,617 shares in the company, valued at approximately $103,404. This represents a 15.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Scott Bizily also recently made the following trade(s):
- On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total value of $19,947.00.
- On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $117,720.00.
4D Molecular Therapeutics Price Performance
Shares of 4D Molecular Therapeutics stock opened at $14.55 on Tuesday. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. The company has a market cap of $760.67 million, a PE ratio of -5.53 and a beta of 2.73. The business has a 50 day moving average of $11.06 and a 200 day moving average of $9.93. 4D Molecular Therapeutics, Inc. has a 52 week low of $5.97 and a 52 week high of $15.03.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current year.
Institutional Investors Weigh In On 4D Molecular Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE bought a new position in shares of 4D Molecular Therapeutics during the second quarter valued at approximately $14,905,000. Man Group plc bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $909,000. Trails Edge Capital Partners LP purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $29,631,296,000. Jupiter Topco LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $76,466,000. Finally, Canada Pension Plan Investment Board bought a new position in 4D Molecular Therapeutics during the 2nd quarter valued at approximately $329,000. Hedge funds and other institutional investors own 99.27% of the company's stock.
Analysts Set New Price Targets
FDMT has been the topic of several research analyst reports. The Goldman Sachs Group reiterated a "buy" rating and set a $32.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday. B. Riley Financial restated a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday. Wall Street Zen cut 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.62.
View Our Latest Research Report on 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
